Quantcast

Latest Quinazolines Stories

56a2b42491908ae0714aac35ed4f3a801
2010-01-19 13:45:40

Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber Cancer Institute and Massachusetts General Hospital (MGH) Cancer Center scientists report in the January issue of Cancer Cell. The findings suggest that identifying such patients and treating them with a combination of drugs from the very start of therapy can produce...

2010-01-07 17:59:26

The interaction of enzymes "“ especially the tyrosine kinases called Src and inducible nitric oxide synthase "“ plays an important role in the growth of non-small cell lung cancers, the most common form of this deadly disease in the United States, said researchers from Baylor College of Medicine in a report in the Journal of Biological Chemistry. Such cancers require activation of the epidermal growth factor receptor, said Dr. Tony Eissa, professor of medicine "“ pulmonary,...

3eec8da6a58c8dbc8d08e7d2634eff8b1
2009-12-24 07:15:00

The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team of Dana-Farber Cancer Institute scientists to discover a compound capable of halting a common type of drug-resistant lung cancer. In a study to be published in the December 24/31 issue of the journal Nature, the researchers report that non-small cell lung cancers that had become invulnerable to the drugs Iressaâ and Tarcevaâ were stymied by a compound...

2009-12-17 15:08:00

Panel Votes Against Approval of Tarceva(R) as Maintenance Drug WASHINGTON, Dec. 17 /PRNewswire-USNewswire/ -- Yesterday, an advisory committee to the Food and Drug Administration voted against the approval of Tarceva(R) (erlotinib) as maintenance treatment for advanced lung cancer patients. (Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO) The Drug Evaluation and Research Oncologic Drugs Advisory Committee (ODAC), a panel of independent medical and scientific experts and...

2009-12-17 10:30:00

WALTHAM, Mass., Dec. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom. The new Special European...

2009-12-12 11:09:27

Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center. Blackwell presented the findings Dec. 10 at the CTRC-AACR San Antonio Breast Cancer Symposium. Blackwell says the combination targeted therapy gave patients more than a four-month survival advantage over those who took lapatinib alone....

2009-12-11 12:30:00

LONDON and PHILADELPHIA, Dec. 11 /PRNewswire/ -- In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9...

2009-12-09 17:41:02

Drug resistant lung cancer cells change their behavior in ways we do not understand to evade treatment, but these events can now be recapitulated and studied in mice Lung cancer is the leading cause of cancer mortality worldwide and lung adenocarcinoma is the most common type. Many cases of lung adenocarcinoma are attributed to a mutation in a gene for the epidermal growth factor receptor (EGFR). Lung cancer with changes in EGFR is initially treatable with a family of chemotherapeutic agents...

2009-10-08 11:07:23

UH Case Medical Center study in JCO reinforces focus on personalized treatment for patients based on ethnicity Clinical research out of University Hospitals Case Medical Center has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs. Published online in the Journal of Clinical Oncology, the study by Rom Leidner, MD, and colleagues report that ethnicity plays a...

2009-09-08 14:53:04

Use of the molecularly targeted agent lapatinib to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While results of this study were largely negative, patients that exhibited toxicity from the drug in the form of a skin rash appeared to have a greater tumor response and longer survival. Findings of this phase II, multi-institutional study are published in Clinical Cancer Research, a...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related